CORBUS PHARMACEUTICALS HOLDI (CRBP)
US21833P3010 - Common Stock
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment...
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and...
Notable Monday Option Activity: CRBP, ATSG, NBR
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight...
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that...
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and...
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that...
Corbus Pharmaceuticals Holdings is Now Oversold (CRBP)
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Shares of Corbus, which is working on a similar drug, also crashed on Novo Nordisk's news.
Noteworthy Wednesday Option Activity: PAG, CRBP, NNOX